MERCK Kommanditgesellschaft auf Aktien
MER
Rang in aandelen
#323
Globally, MERCK Kommanditgesellschaft auf Aktien conducts operations across the... Globally, MERCK Kommanditgesellschaft auf Aktien conducts operations across the healthcare, life science, and electronics sectors. The company is actively involved in the research, development, production, and commercialization of both pharmaceutical and biological prescription medications. These treatments target a range of medical conditions, including those in neurology, immunology, oncology, fertility, and cardiometabolic and endocrine disorders. Furthermore, its life science division furnishes essential products, instruments, and services to support research facilities, pharmaceutical and biotechnology manufacturing, and industrial as well as analytical testing laboratories. Within its electronics segment, MERCK supplies crucial materials for integrated circuits, liquid crystals, organic light-emitting diodes (OLEDs), photoresists, smart antenna systems, and liquid crystal glazing solutions. It also produces specialized effect pigments extensively utilized in applications such as automotive coatings, cosmetics, and various industrial and plastics manufacturing. MERCK maintains strategic partnerships with Pfizer Inc., has an agreement with Novartis AG, and holds license arrangements with Debiopharm International SA and MoonLake Immunotherapeutics AG. Established in 1668, the firm's headquarters are located in Darmstadt, Germany, and it operates as a subsidiary of E. Merck Kommanditgesellschaft.
Aandeelprijs
$171.67
Laatst gesynchroniseerd: 2026-07-13
Marktkapitalisatie
$74.64B
Verandering (1 dag)
0.00%
Verandering (1 jaar)
-
Land
DE
Handel MERCK Kommanditgesellschaft auf Aktien (MER)
Categorie
Healthcare
Winst voor MERCK Kommanditgesellschaft auf Aktien (MER)
Winst in 2026 TTM: 0
Volgens de meest recente financiële verslagen van MERCK Kommanditgesellschaft auf Aktien bedraagt de huidige winst van het bedrijf 0. In 2026 behaalde het bedrijf een winst van 0, gelijk aan de winst van 2026, die 0 bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van MERCK Kommanditgesellschaft auf Aktien van 2002 tot 2026
Winst aan het einde van elk jaar
| Jaar | Winst | Wijzigen |
|---|---|---|
| 2025 | $3.88B | -15.61% |
| 2022 | $4.60B | 3.06% |
| 2021 | $4.46B | 39.31% |
| 2020 | $3.20B | 64.54% |
| 2019 | $1.95B | 15.95% |
| 2018 | $1.68B | -37.09% |
| 2017 | $2.67B | 17.75% |
| 2016 | $2.27B | 40.42% |
| 2015 | $1.61B | -14.32% |
| 2014 | $1.88B | -1.34% |
| 2013 | $1.91B | 104.18% |
| 2012 | $935.24M | -15.11% |
| 2011 | $1.10B | -4.30% |
| 2010 | $1.15B | 65.07% |
| 2009 | $697.43M | -12.95% |
| 2008 | $801.20M | -594.25% |
| 2007 | $-162.10M | -109.67% |
| 2006 | $1.68B | 58.74% |
| 2005 | $1.06B | -18.97% |
| 2004 | $1.30B | 144.81% |
| 2003 | $532.17M | 23.21% |
| 2002 | $431.92M | 0.00% |
Winst van vergelijkbare bedrijven of concurrenten
| Bedrijf | Winst | Winstverschil | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | - |
IN
|
|
| - | - |
CN
|
